摘要
目的观察重组人脑利钠肽联合硝普钠治疗急性心衰的临床疗效、安全性以及预后。方法选取2019年10月~2020年10月在我院诊治的116例急性心衰患者为研究对象,采用随机数字表法分为对照组和观察组,各58例。对照组采用硝普钠治疗,观察组在对照组基础上联合重组人脑利钠肽治疗,比较两组临床治疗总有效率、心功能指标、血清NT-proBNP、hs-CRP、cTnI水平、临床不良反应发生率以及随访1年不良心血管事件发生率。结果观察组治疗总有效率为96.55%,高于对照组的84.48%,差异有统计学意义(P<0.05);治疗后两组心率、左心房内径、左心室内径均低于治疗前,LVEF均高于治疗前,且观察组心率、左心房内径、左心室内径均低于对照组,LVEF均高于对照组,差异有统计学意义(P<0.05);治疗后两组血清NT-proBNP、hs-CRP、cTnI均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为6.89%,与对照组的5.17%比较,差异无统计学意义(P>0.05);随访1年,观察组不良心血管事件发生率为10.34%,低于对照组的22.41%,差异有统计学意义(P<0.05)。结论重组人脑利钠肽联合硝普钠治疗急性心衰,可提高治疗总有效率,促进心率恢复,降低NT-proBNP、hs-CRP、cTnI水平,改善心脏功能,降低远期不良心血管事件,且不会增加临床不良反应。
Objective To observe the clinical efficacy,safety and prognosis of recombinant human brain natriuretic peptide combined with sodium nitroprusside in the treatment of acute heart failure.Methods A total of 116 patients with acute heart failure who were diagnosed and treated in our hospital from October 2019 to October 2020 were selected as the research objects.They were divided into a control group and an observation group using a random number table method,with 58 cases in each group.The control group was treated with sodium nitroprusside,and the observation group was treated with recombinant human brain natriuretic peptide on the basis of the control group.The total effective rate of clinical treatment,cardiac function indexes,serum NT-proBNP,hs-CRP,cTnI levels,the incidence of clinical adverse reactions and the incidence of adverse cardiovascular events were compared between the two groups of clinical treatment.Results The total effective rate of treatment in the observation group was 96.55%,which was higher than 84.48%in the control group,the difference was statistically significant(P<0.05);After treatment,the heart rate,left atrium inner diameter,and left ventricular diameter of the two groups were lower than before treatment,and LVEF was higher than before treatment,and the heart rate,left atrium inner diameter,and left ventricular diameter of the observation group were lower than those of the control group,and the LVEF was higher than that of the control group,the difference was statistically significant(P<0.05);After treatment,the serum NT-proBNP,hs-CRP and cTnI of the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);The incidence of adverse reactions in the observation group was 6.89%,compared with 5.17%in the control group,the difference was not statistically significant(P>0.05);After 1 year of follow-up,the incidence of adverse cardiovascular events in the observation group was 10.34%,which was low
作者
赵寻
张晓磊
朱家旺
ZHAO Xun;ZHANG Xiao-lei;ZHU Jia-wang(Emergency Department of the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300150,China)
出处
《医学信息》
2021年第9期153-155,共3页
Journal of Medical Information
关键词
重组人脑利钠肽
硝普钠
急性心衰
Recombinant human brain natriuretic peptide
Sodium nitroprusside
Acute heart failure
